Sansure Biotech Inc.

Shanghai Stock Exchange 688289.SS

Sansure Biotech Inc. Current Liabilities for the year ending December 31, 2023: USD 129.46 M

Sansure Biotech Inc. Current Liabilities is USD 129.46 M for the year ending December 31, 2023, a -43.16% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Sansure Biotech Inc. Current Liabilities for the year ending December 31, 2022 was USD 227.76 M, a 117.97% change year over year.
Sansure Biotech Inc. Current Liabilities for the year ending December 31, 2021 was USD 104.49 M, a -0.96% change year over year.
Sansure Biotech Inc. Current Liabilities for the year ending December 31, 2020 was USD 105.51 M, a 901.50% change year over year.
Sansure Biotech Inc. Current Liabilities for the year ending December 31, 2019 was USD 10.53 M, a -50.09% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shanghai Stock Exchange: 688289.SS

Sansure Biotech Inc.

CEO	Mr. Lizhong Dai
IPO Date	Aug. 28, 2020
Location	China
Headquarters	No. 680, Lusong Road
Employees	2,006
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

Key trends

Past 5 years